AR053154A1 - Metodo de tratamiento y combinacion de roflumilast y un inhibidor de integrina - Google Patents

Metodo de tratamiento y combinacion de roflumilast y un inhibidor de integrina

Info

Publication number
AR053154A1
AR053154A1 ARP060100780A ARP060100780A AR053154A1 AR 053154 A1 AR053154 A1 AR 053154A1 AR P060100780 A ARP060100780 A AR P060100780A AR P060100780 A ARP060100780 A AR P060100780A AR 053154 A1 AR053154 A1 AR 053154A1
Authority
AR
Argentina
Prior art keywords
treatment
pharmaceutical dosage
roflumilast
pharmaceutically acceptable
dosage forms
Prior art date
Application number
ARP060100780A
Other languages
English (en)
Inventor
Harpreet K Sandhu
David J Valacer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR053154A1 publication Critical patent/AR053154A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formas solidas de dosificacion farmacéutica para administracion oral que consisten una cantidad terapéuticamente activa de roflumilast, o una sal farmacéuticamente aceptable del mismo, una cantidad terapéuticamente efectiva del éster de N-(2-cloro-6- metilbenzoil)-4-[(2-,6-diclorobenzoil)amino]-L-fenilalanina-2-(dietilamino)etilo, o una sal farmacéuticamente aceptable del mismo y uno o mas excipientes farmacéuticamente aceptables. Estas nuevas formas solidas de dosificacion farmacéutica son utiles en el tratamiento o control del asma. También un método para el tratamiento del asma que utiliza las formas solidas de dosificacion farmacéutica y un método para preparar dichas formas de dosificacion farmacéutica.
ARP060100780A 2005-03-04 2006-03-02 Metodo de tratamiento y combinacion de roflumilast y un inhibidor de integrina AR053154A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65871905P 2005-03-04 2005-03-04

Publications (1)

Publication Number Publication Date
AR053154A1 true AR053154A1 (es) 2007-04-25

Family

ID=36888791

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100780A AR053154A1 (es) 2005-03-04 2006-03-02 Metodo de tratamiento y combinacion de roflumilast y un inhibidor de integrina

Country Status (4)

Country Link
US (1) US20060198889A1 (es)
AR (1) AR053154A1 (es)
TW (1) TW200700075A (es)
WO (1) WO2006094640A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
KR101179012B1 (ko) 2003-03-10 2012-09-03 니코메드 게엠베하 로플루미라스트 신규한 제조 방법
EP1861074B1 (en) * 2005-03-16 2013-04-24 Takeda GmbH Taste masked dosage form containing roflumilast
WO2013030789A1 (en) * 2011-08-30 2013-03-07 Ranbaxy Laboratories Limited Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor
CN102949370B (zh) * 2012-11-27 2018-05-04 贵州信邦制药股份有限公司 一种罗氟司特片及其制备方法和检测方法
WO2021213455A1 (zh) * 2020-04-23 2021-10-28 浙江养生堂天然药物研究所有限公司 药物组合及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100331255B1 (ko) * 1993-07-02 2002-10-25 빅굴덴 롬베르그 케미쉐 화부리크 게엠베하 플루오로알콕시-치환된벤즈아미드및시클릭뉴클레오티드포스포디에스테라아제억제제로서의그의용도
US6229011B1 (en) * 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
US6455550B1 (en) * 1997-08-22 2002-09-24 Hoffmann-La Roche Inc. N-alkanoylphenylalanine derivatives
MXPA01008178A (es) * 1999-02-18 2002-03-13 Hoffmann La Roche Derivados de fenilalaninol.
ES2228458T3 (es) * 1999-02-18 2005-04-16 F. Hoffmann-La Roche Ag Derivados de tioamida.
MXPA02001830A (es) * 1999-08-21 2002-08-12 Byk Gulden Lomberg Chem Fab Combinacion sinergica de inhibidores de pde y agonista de beta 2 adrenoceptor.
US6388084B1 (en) * 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
US6380387B1 (en) * 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
US6734311B2 (en) * 2000-05-22 2004-05-11 Merck & Co., Inc. Substituted amidine derivatives as inhibitors of cell adhesion
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
WO2006066780A1 (en) * 2004-12-22 2006-06-29 F. Hoffmann-La Roche Ag Combinations of valategrast and montelukast for treating asthma

Also Published As

Publication number Publication date
WO2006094640A3 (en) 2006-12-28
US20060198889A1 (en) 2006-09-07
WO2006094640A2 (en) 2006-09-14
TW200700075A (en) 2007-01-01

Similar Documents

Publication Publication Date Title
NO20051966L (no) Nye pyrimidinamidderivater og anvendelse derav
AR052567A1 (es) Combinacion de bambuterol e inhibidor de integrina
AR052062A1 (es) Composicion y metodo para tratar el asma
NO20076613L (no) Farmasoytiske formuleringer og anvendelse derav
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
DE60332629D1 (de) Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yi)aminderivate
ATE511392T1 (de) Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit
NO20055173L (no) Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel
AR053154A1 (es) Metodo de tratamiento y combinacion de roflumilast y un inhibidor de integrina
WO2007137247A3 (en) Treatment for depressive disorders
AR045572A1 (es) Una combinacion que comprende n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil-3-sulfonamida y un analogo lhrh y/o un bifosfonato
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
ATE413187T1 (de) Pharmazeutische zusammensetzungen mit interferon- tau
MA31227B1 (fr) Composition pharmaceutique renfermant du phloroglucinol et du paracetamol.
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
SE0000303D0 (sv) Novel compounds
BRPI0407850A (pt) processo para fabricação de uma composição farmacêutica contendo o princìpio ativo fenofibrato ou de um de seus derivados, e, comprimido de fenofibrato ou de um de seus derivados
AR045074A1 (es) Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
SE0203817D0 (sv) New composition
BR112023023715A2 (pt) Pluralidade de partículas compreendendo tasquinimod, composição farmacêutica, unidade de dosagem farmacêutica, uso da pluralidade de partículas ou da composição farmacêutica, e, método para o tratamento do câncer
RU2009107917A (ru) Аминоизохинолиновый ингибитор тромбина с улучшенной биодоступностью
TH80954B (th) สารผสมและวิธีการสำหรับการบำบัดโรคหอบหืด
CL2004000319A1 (es) Combinacion farmaceutica que comprende edotecarina o una sal farmaceuticamente aceptable y docetaxel o capacitabina, kit terapeutico, util para el tratamiento del cancer.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal